Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats

Adiponectin overexpression promotes fracture healing through regulating the osteogenesis and adipogenesis balance in osteoporotic mice

INTRODUCTION

Osteoporosis invariably manifests as loss of bone, which is replaced by adipose tissue; this can easily lead to fractures, accompanied by delayed and poor healing. Adiponectin (APN) balances osteogenesis and adipogenesis in bone marrow mesenchymal stem cells (BMSCs). Therefore, this study explored whether adiponectin promotes bone fracture healing by regulating the balance between osteogenesis and adipogenesis.

MATERIALS AND METHODS

We used adenovirus overexpression vectors carrying APN (Ad-APN-GFP) to treat ovariectomized (OVX) mouse BMSCs and osteoporotic bone fractures to investigate the role of APN in bone microenvironment metabolism in osteoporotic fractures. We subsequently established an OVX mice and bone fracture model using Ad-APN-GFP treatment to investigate whether APN could promote bone fracture healing in osteoporotic mice.

RESULTS

The experimental results showed that APN is a critical molecule in diverse differentiation directions in OVX mouse BMSCs, with pro-osteogenesis and anti-adipogenesis properties. Importantly, our study revealed that Ad-APN-GFP treatment facilitates bone generation and healing around the osteoporotic fracture ends. Moreover, we identified that Sirt1 and Wnt signaling were closely related to the pro-osteogenesis and anti-adipogenesis commitment of APN in OVX mouse BMSCs and femoral tissues.

CONCLUSION

We demonstrated that APN overexpression facilitates bone fracture healing in osteoporosis. Furthermore, APN overexpression promoted bone formation in OVX mouse BMSCs and bone fracture ends by regulating the balance between osteogenesis and adipogenesis both in vitro and in vivo.

Adenoviral delivery of adiponectin ameliorates osteogenesis around implants in ovariectomized rats

BACKGROUND

Adiponectin (APN) has been reported to promote bone formation. However, it is difficult to utilize a conventional method that administers sufficient APN to the implant site. The present study investigated the efficacy of an APN transgene to accelerate the implant osseointegration in ovariectomized (OVX) rats.

METHODS

In vitro, bone marrow stromal cells were transduced with reconstructed adenovirus (Ad-APN-EGFP) and osteoclast precursor RAW264.7 cells were co-cultured with the conditioned medium secreted by transduced bone marrow stromal cells. Tartrate-resistant acid phosphatase staining and bone slice resorption assay were performed to evaluate the activity of osteoclastogenesis. In vivo, Ad-APN-EGFP was administered into the bone defect prior to implant placement in OVX rats. At 7 and 28 days post implantation, the femurs were harvested and prepared for a real-time reverse transcriptase-polymerase chain reaction, hemotoxylin and eosin staining, immunohistochemical staining, micro-computed tomography analysis and biomechanical testing.

RESULTS

The results showed the formation and function of osteoclasts were significantly suppressed in vitro. Successful transgene expression was confirmed, and a significant increase of OCN, Runx2 and ALP expression was detected in the Ad-APN-EGFP group in vivo. Interestingly, we also found that the overexpression of APN decreased the expression level of potent adipogenic transcription factors such as PPARγ2 and C/EBP-α. At 28 days after implantation, the Ad-APN-EGFP group revealed a significantly increased osseointegration and implant stability in OVX rats compared to the control groups (Ad-EGFP and PBS groups).

CONCLUSIONS

APN via direct adenovirus-mediated gene transfer could ameliorate osseointegration surrounding titanium implants in OVX-related osteoporosis rats. Furthermore, it may be an effective strategy for promoting bone regeneration under osteoporotic conditions.

Effect of Human Wnt10b Transgene Overexpression on Peri-Implant Osteogenesis in Ovariectomized Rats

This study aimed to investigate the efficacy of human Wnt10b (hWnt10b) transgene expression in ovariectomized (OVX) rats to accelerate osseointegration around titanium implants, and to provide a new strategy for treating osteoporosis with implants. An in vivo osteoporosis model was generated via bilateral ovariectomy in rats, and changes in expression of Wnt pathway-related genes were investigated. In OVX rats with a femur defect, hWnt10b expressed from an adenovirus vector was locally delivered to the defect site prior to implant placement. Surrounding femur tissues were collected 1 and 3 weeks after implantation for imaging, biomechanical testing, and molecular and histological analyses. In an in vitro model, bone-marrow stromal cells (BMSCs) transfected with adenovirus containing hWnt10b (Ad-hWnt10b) were cultured for 2 weeks in adipogenic medium followed by 2 weeks in osteogenic induction medium. Alizarin Red staining and Oil Red O staining, as well as reverse transcription polymerase chain reaction and Western blot analyses, were performed to assess the effect of hWnt10b expression on BMSC differentiation. Expression of Wnt pathway genes was significantly downregulated in OVX rats. OVX rats treated with Ad-hWnt10b prior to induction of a femur defect showed markedly increased ALP, Runx-2, and osteocalcin expression and decreased cathepsin K expression. Histological and imaging analysis showed increases in the number of osteocalcin-positive cells and the density of newly formed bone surrounding the implant in the Ad-hWnt10b group relative to the untreated control. Meanwhile, Ad-hWnt10b-BMSCs showed significantly increased osteogenesis and decreased adipogenesis. hWnt10b may accelerate osseointegration around implants and subsequently enhance bone regeneration and implant stabilization under OVX conditions.

Osteoprotegerin gene-modified BMSCs with hydroxyapatite scaffold for treating critical-sized mandibular defects in ovariectomized osteoporotic rats

Women with postmenopausal osteoporosis are at a high risk for fracture as their bone resorption rate exceeds bone formation rate, resulting in decreased bone mineral density and microarchitectural deterioration. Osteoprotegerin (OPG), a known therapeutic agent capable of inhibiting osteoclastogenesis, has been used in treatment of chronic bone resorptive diseases. On the other hand, bone mesenchymal stem cells (BMSCs) play an important role in bone formation. To inhibit excessive bone resorption and increase bone formation, we developed a novel therapeutic strategy by genetically modifying BMSCs for OPG delivery. The OPG gene-modified BMSCs were seeded on hydroxyapatite (HA) scaffolds to promote bone regeneration in critical-sized mandibular bone defects in ovariectomy (OVX) induced osteoporotic rats. Rat BMSCs were infected with human OPG adenoviruses (OPG-BMSCs). The gene-modified cells expressed higher OPG gene level than the control Ad-BMSCs (p<0.05) and maintained high expression of OPG protein for more than 2weeks. Our in vitro bone resorption experiment demonstrated that OPG-BMSCs were capable to suppress osteoclast differentiation and subsequently inhibit osteoclast-mediated bone resorption. The micro-CT and histological results showed that HA-OPG-BMSC constructs boosted bone formation and reduced osteoclastogenesis in OVX rat mandibular bone defects. In conclusion, the novel OPG-BMSC-HA constructs were demonstrated to be able to orchestrate bone-forming BMSCs and bone-resorbing osteoclasts, with the potential for osteoporotic-related bone defect reconstruction applications.

STATEMENT OF SIGNIFICANCE

Women with postmenopausal osteoporosis are at a high risk for fracture as their bone resorption rate exceeds bone formation rate. Osteoprotegerin (OPG), a known therapeutic agent capable of inhibiting osteoclast cells, has been used in treatment of chronic bone resorptive diseases. To inhibit excessive bone resorption and increase bone formation, we developed a novel therapeutic strategy by genetically modifying bone marrow stem cells (BMSCs) for OPG delivery and seeding the cells on a hydroxyapatite (HA) scaffold for in vivo bone defect repair. The novel OPG-BMSC-HA constructs were able to orchestrate bone-forming BMSCs and bone-resorbing osteoclasts, demonstrating good potential for osteoporosis-related bone defect reconstruction treatments.

Impact of Different Promoters on Episomal Vectors Harbouring Characteristic Motifs of Matrix Attachment Regions

We previously demonstrated that the characteristic sequence of matrix attachment regions (MARs) allows transgenes to be maintained episomally in CHO cells. In the present study, six commonly used promoters from human cytomegalovirus major immediate-early (CMV), simian vacuolating virus 40 (SV40), Rous sarcoma virus, Homo sapiens ubiquitin C, phosphoglycerate kinase, and β-globin, respectively, were evaluated to determine their effects on transgene expression and stability in CHO cells stably transfected via the episomal vector harbouring characteristic MAR motifs. The CHO cells were transfected with vectors and then screened using G418, after which the stably transfected cells were split into two and further cultured either in the presence or absence of G418. Of the six promoters, the CMV promoter yielded the highest transgene expression levels and the highest transfection efficiency, whereas the SV40 promoter maintained transgene expression more stably during long-term culture than the other promoters did. The CMV and SV40 promoter-containing vectors were furthermore episomally maintained and conferred sustained eGFP expression in the cells even under nonselective conditions. On the basis of these findings, we conclude that the CMV promoter performs best in terms of yielding both high expression levels and high levels of stability using this episomal vector system.

Regenerative Medicine for Periodontal and Peri-implant Diseases

The balance between bone resorption and bone formation is vital for maintenance and regeneration of alveolar bone and supporting structures around teeth and dental implants. Tissue regeneration in the oral cavity is regulated by multiple cell types, signaling mechanisms, and matrix interactions. A goal for periodontal tissue engineering/regenerative medicine is to restore oral soft and hard tissues through cell, scaffold, and/or signaling approaches to functional and aesthetic oral tissues. Bony defects in the oral cavity can vary significantly, ranging from smaller intrabony lesions resulting from periodontal or peri-implant diseases to large osseous defects that extend through the jaws as a result of trauma, tumor resection, or congenital defects. The disparity in size and location of these alveolar defects is compounded further by patient-specific and environmental factors that contribute to the challenges in periodontal regeneration, peri-implant tissue regeneration, and alveolar ridge reconstruction. Efforts have been made over the last few decades to produce reliable and predictable methods to stimulate bone regeneration in alveolar bone defects. Tissue engineering/regenerative medicine provide new avenues to enhance tissue regeneration by introducing bioactive models or constructing patient-specific substitutes. This review presents an overview of therapies (e.g., protein, gene, and cell based) and biomaterials (e.g., resorbable, nonresorbable, and 3-dimensionally printed) used for alveolar bone engineering around teeth and implants and for implant site development, with emphasis on most recent findings and future directions.